Biotech | February 23, 2022
Merck completes acquisition of biopharma CDMO Exelead
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
US $ 555,000 invested by Wavemaker Partners in pre-seed round
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Subscribe To Our Newsletter & Stay Updated
